ArticleCombinatorial chemistry & high throughput screening2026
Active Components and Potential Mechanism of Redujing Oral Liquid for Treating EBV Infection: A UHPLC-MS and Network Pharmacology- Based Approach.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionDiseases associated with Epstein-Barr Virus (EBV) infection present substantial health challenges. While Redujing Oral Liquid (RDJ) has demonstrated efficacy against EBV in preclinical and clinical studies, its active components and mechanisms of action remain unclear. This study aimed to systematically characterize RDJ's chemical profile and dissect its anti-EBV mechanisms using Ultra-High-Performance Liquid Chromatography-Mass Spectrometry (UHPLC-MS) and network pharmacology.
methodUltra-High Performance Liquid Chromatography coupled with Quadrupole-Orbitrap Tandem Mass Spectrometry (UHPLC-Q-Orbitrap MS/MS) was employed to identify chemical components in RDJ. EBV infection-related targets were retrieved from GeneCards and Online Mendelian Inheritance in Man (OMIM) databases to construct a "component-target-disease" network. Protein-Protein Interaction (PPI) networks were built via Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) to screen key targets, while Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses via Database for Annotation, Visualization, and Integrated Discovery (DAVID) elucidated functional and pathway enrichments. Molecular docking and dynamics simulations validated interactions between active components and core targets.
resultsA total of 147 chemical components were identified in RDJ, with flavonoids as the most abundant class. Network pharmacology revealed that RDJ may exert anti-EBV effects through active components (e.g., 7,2-dihydroxy-3',4'-dimethoxyflavone, alpha-methyl-n-butyl shikonin, isobutyl shikonin, norwogonin, baicalein) targeting key proteins, for example, TP53, SRC, STAT3, PIK3CA, and AKT1. Molecular docking and dynamics simulations showed a strong binding affinity between baicalein and PIK3CA, a core target. DISCUSSION: The multi-component, multi-target nature of RDJ suggests its anti-EBV efficacy arises from modulating diverse signaling pathways, with baicalein-PIK3CA interactions as a potential key mechanism. These findings align with RDJ's clinical utility and provide mechanistic insights for EBV-related disease therapy.
conclusionThis study systematically characterized the active components of RDJ and revealed its anti-EBV mechanisms through an integrated approach combining chemical profiling and network pharmacology. The identified components and pathways, particularly baicalein-mediated regulation of PIK3CA, offer a theoretical foundation for advancing RDJ in clinical and translational research for EBV-associated diseases.
Indexed as
Identifiers
41830144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.